Shareholder Alert: Ademi LLP investigates whether CinCor Pharma, Inc. has obtained a Fair Price in its transaction with AstraZeneca

MILWAUKEE, Jan. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating CinCor (Nasdaq: CINC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca. 

Click here to learn how to join the action https://www.ademilaw.com/case/cincor-pharma-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Ademi LLP alleges CinCor's financial outlook and prospects are excellent and yet CinCor shareholders will receive only $26 per share in cash at closing plus a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission of a baxdrostat product. The transaction agreement unreasonably limits competing bids for CinCor by imposing a significant penalty if CinCor accepts a superior bid. CinCor insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of CinCor's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for CinCor.

If you own CinCor common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/cincor-pharma-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                                       
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP